Display options
Cite
Kofler K, Strölin A, Geiger V, et al. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level. J Cutan Med Surg. 2021;25(5):504-510doi: 10.1177/12034754211003525.
Kofler, K., Strölin, A., Geiger, V., & Kofler, L. (2021). Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level. Journal of cutaneous medicine and surgery, 25(5), 504-510. https://doi.org/10.1177/12034754211003525
Kofler, Katrin, et al. "Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level." Journal of cutaneous medicine and surgery vol. 25,5 (2021): 504-510. doi: https://doi.org/10.1177/12034754211003525
Kofler K, Strölin A, Geiger V, Kofler L. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level. J Cutan Med Surg. 2021 Sep;25(5):504-510. doi: 10.1177/12034754211003525. Epub 2021 Mar 28. PMID: 33779349; PMCID: PMC8474298.
Copy Download .nbib Format: NLM
Share it on

J Cutan Med Surg. 2021 Sep;25(5):504-510. doi: 10.1177/12034754211003525. Epub 2021 Mar 28.

Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

Journal of cutaneous medicine and surgery

Katrin Kofler, Anke Strölin, Vanessa Geiger, Lukas Kofler

Affiliations

  1. 9188 Department of Dermatology, Eberhard-Karls University, Tübingen, Germany.

PMID: 33779349 PMCID: PMC8474298 DOI: 10.1177/12034754211003525

Abstract

BACKGROUND: Livedoid vasculopathy (LV) is a rare disease characterized by livedo racemosa, atrophie blanche, ulcerations, and severe pain. Low molecular weight heparins and rivaroxaban can be used in LV-patients. In addition, intravenous immunoglobulins (IVIG) have been described as treatment-option.

OBJECTIVES: Objective was to investigate the therapeutic effect of IVIG on ulcer, pain and restrictions in daily life.

METHODS: Thirty-two LV-patients who received IVIG at the Department of Dermatology Tübingen between 01/2014 and 06/2019 were identified. Twenty-five of these patients were available for further follow up and were included in the study. Patients were interviewed using a questionnaire focusing on the course of the disease, symptoms, and subjective response to IVIG-treatment.

RESULTS: Twenty-five patients were included in the study (mean follow up: 28.9 months). Patients received an average of 6.8 cycles (range 1-45) of IVIG during the observed period.Significant improvements were seen regarding skin findings, pain, and limitation of daily activities. Complete remission of symptoms was observed in 68% of patients. Good tolerability of IVIG was shown in 92%.

CONCLUSIONS: A good therapy response regarding ulceration, pain, and daily life restrictions with good tolerability was demonstrated for IVIG (2 g/kg bodyweight over 5 days).

Keywords: intravenous immunoglobulin; livedo reticularis; livedoid vasculopathy; ulceration

References

  1. N Engl J Med. 2012 Nov 22;367(21):2015-25 - PubMed
  2. Neurology. 2003 Jun 10;60(11):1822-4 - PubMed
  3. Acta Derm Venereol. 2018 Oct 10;98(9):842-847 - PubMed
  4. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791 - PubMed
  5. Arch Dermatol. 2006 Nov;142(11):1413-8 - PubMed
  6. Autoimmun Rev. 2011 Apr;10(6):353-60 - PubMed
  7. Int J Dermatol. 2013 Sep;52(9):1135-9 - PubMed
  8. Thromb Res. 2014 Jun;133(6):1045-51 - PubMed
  9. Br J Dermatol. 2006 Oct;155(4):714-21 - PubMed
  10. Acta Paediatr Jpn. 1991 Dec;33(6):791-8 - PubMed
  11. J Am Acad Dermatol. 2014 Oct;71(4):738-44 - PubMed
  12. J Am Acad Dermatol. 2004 Oct;51(4):574-9 - PubMed
  13. Dermatol Ther. 2020 Mar;33(2):e13229 - PubMed
  14. N Engl J Med. 2001 Sep 6;345(10):747-55 - PubMed
  15. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1884-1889 - PubMed
  16. J Am Acad Dermatol. 2014 Nov;71(5):1024-6 - PubMed
  17. Lancet Haematol. 2016 Feb;3(2):e72-9 - PubMed
  18. J Dtsch Dermatol Ges. 2017 Feb;15(2):228-241 - PubMed
  19. J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1340-6 - PubMed
  20. Neurology. 2020 Feb 11;94(6):e635-e638 - PubMed
  21. BioDrugs. 2002;16(1):47-55 - PubMed
  22. Drug Saf. 1999 Sep;21(3):171-85 - PubMed
  23. J Am Acad Dermatol. 2003 Sep;49(3):555-6 - PubMed
  24. Am J Hematol. 2016 Jun;91(6):594-605 - PubMed
  25. J Dtsch Dermatol Ges. 2013 May;11(5):407-10 - PubMed

Publication Types